Renewal of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC)
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The U.S. Department of Health and Human Services and National Institutes of Health are renewing the charter for the National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) for an additional two years effective April 14, 2026. The committee provides expert advice to the NCI Director on the conduct, oversight, and implementation of NCI's clinical trials and translational research programs, which represent one of the agency's largest investments. CTAC consists of up to 25 non-federal members plus federal ex officio members, with an estimated total annual cost of $121,213 for FY 2026. It is the only federal advisory committee focused exclusively on clinical trials and translational research for NCI. The renewal is justified because no other committee offers the same specialized expertise for improving efficiency, addressing gaps in recalcitrant cancers, and ensuring accountability in the use of public funds for cancer research.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Charter renewal effective April 14, 2026 for two years
- Projected FY 2026 total committee cost of $121,213
- Committee size up to 25 non-federal members plus federal ex officio members
+ 3 more changes with Pro